No abstract

For the years 1972-1981, 7 333 isolates of dermatophytes belonging to 14 species were obtained from glabrous skin (32%), feet (28%), groin (19%), scalp (8%), toenails (7%), fingernails (3%) and beard (1%). T. rubrum represented 50% of all the isolates and was the most frequent species on glabrous skin, groin and nails. T. mentagrophytes (24%) was mainly obtained from the feet, E. floccosum (9%) from the groin and T. megninii (4%) from uncovered areas of the skin, fingernail and beard. These 4 species predominated in men. M. canis was the commonest agent on the scalp and in children up to 11 years. T. violaceum, previously the main cause of tinea capitis, and T. tonsurans have been decreasing for the period of this study, just as T. schoenleinii for the years 1962-71. The rising prevalence of T. rubrum was observed since 1962. In the whole it seems stable after 1969, but the analysis of the main sites involved shows that in the glabrous skin this species increased from 1962 to 1974; in the groin it was gone up from 30% during 1962-1965, to 64% in the years 1969-1971; in the feet the evolution was slower and only in 1980 T. rubrum became more frequent than T. mentagrophytes. The increase in certain species, whereas others become rare, lacks a satisfactory explanation.

No abstract

No abstract

In addition to its requirement for histidine, Trichophyton megnmii can be readily differentiated from certain other dermatophytes, particularly Trichophyton rubrum, by its "+" mating type and a positive urease test on urea-indole broth.

ECMhl 2002 55 mg (t.i.d) or 150 mg (b.i.d or t.i.d) PLD-118. Each volunteer received a single dose on the first day, followed by a 72 h wash out period, multiple doses for 7 days, and a single dose on the last dosing day. Plasma samples were collected over 72 h at Day I and Day 11, as well as prior to and 1 hour after the morning dose at Days 4-10. Urine samples were collected up to 72 hours after the last dose.Results: Steady state plasma concentrations were achieved within 2-3 days of multiple dosing. Average C,,, during the stady state ranged from 2.0 to 5.7 pg/mL and Cmin from 0.7 to 2.3 pg/mL in the 50 mg and 150 mg t.i.d group, respectively. Half-life of PLD-I 18 in plasma was around 7 h. Over 80% of the dose was recovered in urine in unchanged form. PLD-I 18 was well tolerated. The most frequent adverse event was dry mouth, occurring in 5 subjects. EEG abnormalities were detected in 2 subjects receiving PLD-I 18 and in 2 receiving placebo. There were no clinically significant drugrelated changes of vital signs, ECG parameters or laboratory findings. Conclusion:Presented results suggest good tolerability and favorable pharmacokinetic profile of PLD-I 18 in healthy male volunteers.

No abstract